Analysis of Human Herpesvirus 6 U3 Gene, which Is a Positional Homolog of Human Cytomegalovirus UL 24 Gene  by Mori, Yasuko et al.
Analysis of Human Herpesvirus 6 U3 Gene, which Is a Positional
Homolog of Human Cytomegalovirus UL 24 Gene
Yasuko Mori, Hirotaka Yagi,* Takuya Shimamoto,* Yuji Isegawa,* Tomimasa Sunagawa,* Reiko Inagi,*
Kazuhiro Kondo,* Yasuo Tano,† and Koichi Yamanishi*,1
Departments of *Microbiology and †Ophthalmology, Osaka University Medical School, 2–2 Yamada-oka, Suita, Osaka 565-0871, Japan
Received March 16, 1998; returned to author for revision May 15, 1998; accepted June 19, 1998
The US22 gene family was first discovered in human cytomegalovirus (HCMV) and contains several conserved amino acid
motifs. Human herpesvirus 6 (HHV-6) also encodes several genes belonging to the US22 family, including the U3 gene (a
positional homolog of HCMV UL24). Because the gene products of the US22 gene family function as gene regulators in
general, we analyzed the HHV-6A U3 gene. Six transcripts with different molecular weights of 7.5–1.8 kb were detected by
Northern blot analysis using a U3-specific probe. Sequence analyses of the respective cDNA clones and primer extension
experiments revealed that the U3 gene encoded the 2.0- and 3.5-kb transcripts and had no splicing within the U3 gene region.
By immunofluorescence testing using antibodies raised to a fusion protein of MBP (maltose-binding protein) and U3, the U3
viral antigen was detected as early as 24 h p.i. in HHV-6A-infected U373 cells. The antigens were found in cytoplasmic
granules, preferentially in the endoplasmic reticulum. Moreover, cotransfection assay using a luciferase gene expression
system revealed that the U3 gene product was capable of activating the human immunodeficiency virus long terminal repeat
promoter in CV1 cells. © 1998 Academic Press
INTRODUCTION
Human herpesvirus 6 (HHV-6) is a lymphotropic her-
pesvirus first isolated from in vitro cultured peripheral
blood lymphocytes of patients with lymphoproliferative
disorders (Salahuddin et al., 1986) and acquired immuno-
deficiency syndrome (AIDS) (Josephs et al., 1986; Down-
ing et al., 1987; Tedder et al., 1987; Lopez et al., 1988).
HHV-6 is the causative agent of exanthem subitum (Ya-
manishi et al., 1988). Several HHV-6 genes capable of
trans-activation of the human immunodeficiency virus
(HIV) long terminal repeat (LTR) have been identified
(Horvat et al., 1989, 1991; Geng et al., 1992; Martin et al.,
1991; Kashanchi et al., 1994; Nicholas et al., 1994; Wang
et al., 1994; Zhou et al., 1994), and HHV-6 enhanced the
replication of HIV (Ensoli et al, 1989). Thus, HHV-6 ap-
pears to be a cofactor involved in the pathogenesis of
AIDS, whereas in some cases, HHV-6 suppressed in
vitro replication of HIV type 1 (Lopez et al., 1988; Carrigan
et al., 1990).
The double-stranded DNA genome of HHV-6 is 161.5
kbp, containing a 141-kbp unique region bounded by
10-kbp direct repeats (Lindquester et al., 1991; Martin et
al., 1991). DNA sequence analysis of this genome has
demonstrated that HHV-6 is phylogenetically related to
the b-herpesvirus subfamily and is close to human cyto-
megalovirus (HCMV) (Efsthathiou, et al., 1992; Gompels
et al., 1995). There are two HHV-6 variants: HHV-6A and
HHV-6B (Ablashi et al., 1993). The entire genome of
HHV-6A has been sequenced, predicting that the ge-
nome encodes .102 proteins (Gompels et al., 1995). Of
these, 10 open reading frames (ORFs) (DR2, DR7, U2, U3,
U7, U8, U16/U17, U25, and U95) encode one or more
motifs characteristic of the US 22 gene family (Efstathiou
et al., 1992; Thomson and Honess, 1992; Gompels et al.,
1995), which was first found in HCMV (Weston and Bar-
rell, 1986; Kouzarides et al., 1988; Mocarski et al., 1988;
Chee et al., 1990). This family is absent in the genomes
of the human a- and g-herpesviruses. Some of the US 22
family genes encode transactivators for HIV LTR (Geng
et al., 1992; Kashanchi et al., 1994; Nicholas et al., 1994).
In addition, it was recently reported that human herpes-
virus 7 (HHV-7) also has several genes with the US 22
motifs (Nicholas et al., 1996). Both HHV-6 and HHV-7 are
lymphotropic in vitro and in vivo (Lusso et al., 1989;
Takahashi et al., 1989) and are able to replicate in CD41
lymphocytes, which also are permissive for HIV replica-
tion. It is possible that these US22 family genes have a
significant influence in vivo for HIV gene expression.
However, at present, the roles of most members of the
US22 gene family, including those present in HCMV,
HHV-6, and HHV-7, remain unclear. Therefore, it is im-
portant to investigate the biological function of the US22
family members.
In the present study, we focus on HHV-6A U3 gene, a
positional homolog of UL24 in the HCMV genome that
contains characteristic motifs of the US22 gene family
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because their expression and biological functions in
infected cells have not been reported. We identify the U3
gene product in HHV-6A-infected cells, analyze its intra-
cellular localization in an eukaryotic expression system,
and demonstrate the transactivating function of U3 gene
for HIV LTR in vitro.
RESULTS
Transcription analysis of U3 gene
To determine and map mRNA species of U3 gene
transcripts, we first determined the transcriptional pat-
terns for HHV-6A strain U1102 by Northern blot analy-
ses with the various DNA probes (Fig. 1b). Northern
blot analyses of poly(A)1 RNA from infected cells us-
ing 1.1-kb U3F probe revealed six transcripts in sizes of
;7.5, ;5.5, ;3.5, ;2.8, ;2.0, and ;1.8 kb, with the
3.5-kb RNA being the most abundant (Fig. 1a, column
B, lane 2). Next, to determine the boundaries, Northern
blotting was performed with probes corresponding to
regions upstream and downstream of the U3 gene.
Transcripts similar to those detected with U3F probe
were detected with probe U2F, which covered a region
downstream of U3F (Fig. 1a, column A, lane 2); again,
the 3.5-kb RNA was most abundant. The U3A probe
(1.8 kbp) for detecting regions within and upstream of
the U3 gene, hybridized with 7.5-, 5.5-, 4.2-, 3.5-, 2.4-,
and 2.0-kb transcripts (Fig. 1a, column C, lane 2).
However, this hybridization pattern was different from
the U3F pattern in probe U3A, and two transcripts of
4.2 and 2.4 kb were detected with U3A, whereas the
2.8- and 1.8-kb transcripts were not. This suggests that
the 4.2- and 2.4-kb transcripts terminate upstream of
the U3 region and the 2.8-and 1.8-kb transcripts may
initiate within the U3 region. The U4P probe (0.9 kbp)
to localize the upstream of the U3 gene failed to
hybridize with the 3.5-kb transcript (Fig. 1a, column D,
lane 2), indicating that the 2.0- and 3.5-kb transcripts
were initiated downstream of the U4P probe, and was
encoded by U3 gene. On the other hand, the 7.5- and
5.5-kb transcripts hybridized with all of the probes
used here.
FIG. 2. Schematic interpretation of cDNA clones detected by using
U3F probe from cDNA library. (Numbers in bold) cDNA clone num-
ber. (Numbers on right and left of cDNA clones) The nt position
reported by Gompels et al. (1995). The locations of 59 end of cDNA
are indicated in front of each cDNA. Each A1 at the 39 end of cDNA
indicates poly(A)1 site.
FIG. 1. (a) Northern blot analysis. The probes used were (A) U2F, (B)
U3F, (C) U3A, and (D) U4P. The lanes are poly(A)1 RNA (12 mg/track)
from U1102- and mock-infected U373 cells. (Left) Sizes of mRNA (in kb).
Lane 1, Mock-infected U373 cells. Lane 2, Strain U1102-infected cells.
(b) Map positions of the U2F, U3F, U3A, and U4P DNA probes are
shown on the HHV-6A genome. (Numbers) The nt position reported by
Gompels et al. (1995).
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To map mRNAs more precisely, a cDNA library was
constructed from U373 cells infected with strain U1102.
After multiple screening steps, cDNA clones, which hy-
bridized in Southern blot analyses to the radiolabeled
U3F probe, were selected. By screening of 5 3 105
clones, 15 clones were hybridized (Fig. 2). All clones that
were completely sequenced showed the same orienta-
tions of the sense strand. No splicing was detected in
this mapped region.
To map the 59 end of the 2.0- and 3.5-kb U3 transcripts,
the primer extension assay was carried out with oligo 1
primer as shown in Figure 3, and one product was
observed (Fig. 3). A transcription initiation site was de-
tected ;9 nucleotides (nt) upstream of a possible trans-
lation initiation codon. A TATA box-like sequence TATTTC
and TATATTA existed at positions 10–15 and 63–69 bp
upstream of this cap site, respectively. To define the 39
end of the mRNA, the 39 RACE method was carried out
(Fig. 4). The 39 end sites of the 2.0- and 3.5-kb transcripts
seen by Northern blotting were determined to be at 21
and 26 nt downstream of the putative poly(A)1 signal.
Transcript mapping by cDNA sequencing was summa-
rized in Figure 5.
Expression of U3 protein in U373 cells infected
with U1102
Having verified the expression and determined some
properties of the U3 transcripts in U1102 infected cells,
we next attempted to identify the U3 protein in infected
cells. First, indirect IFA was performed in U373 cells
infected with U1102 as a way of verifying that the U3
gene is expressed during infection. Immunofluorescence
patterns using rabbit anti-U3 serum are shown in Figure
6. When U373 cells were infected with U1102, cells
showed large syncytia due to cell fusion (Fig. 6, A-1) but
little infectious virus in culture fluid (data not shown). The
U3 protein became visible by 24 h p.i. and accumulated
to high levels by 72 h p.i. in the cytoplasm, preferentially
in the perinuclear regions of the fused cells (Fig. 6, A-2).
No specific staining was found in mock-infected cells
with anti-U3 serum and in infected cells reacted with
preimmune serum and anti-MBP serum (data not
shown). Although the expression of the U3 protein was
detected in U373 cells infected with U1102, the U3 pro-
tein was not visible in lymphocytic cells (CBMCs and
SupT1) by IFA (data not shown), suggesting the low
expression in lymphocytic cells.
To determine the kinetics of U3 protein expression,
U3 antigen in U373 cells infected with U1102 was
examined by IFA at 48 and 72 h p.i. in the presence of
an inhibitor of viral DNA polymerase, phosphonofor-
mic acid [(PFA) 200 mg/ml]. In the presence of PFA, U3
antigen was not detected by IFA at 48 and 72 h p.i.
(data not shown), indicating that U3 expression might
not occur at an early time p.i. and that U3 antigen
might be a late protein.
Localization of U3 antigen in U373 cells
Understanding the localization of a protein in a cell
provides valuable information on its possible biological
function; therefore, we attempted to define intracellular
localization of U3 protein. For this, we used an overex-
pression system by transfecting the U3-expressing plas-
FIG. 4. Determination of the 39 end of 2.0- and 3.5-kb transcripts. The
putative poly(A)1 signal is underlined and bold. (Arrows) Sites to which
poly(A)1 is added. (Numbers) The nt position reported by Gompels et
al. (1995).
FIG. 3. Primer extension analysis. Transcription initiation sites were
mapped by using 12 mg of poly(A)1 RNA prepared from U1102- and
mock-infected cells (as in Fig. 1). Results obtained with Oligo 1 re-
vealed a transcription initiation sites. (Arrows) The nt recognized for
transcript initiation. (Number) The nt position reported by Gompels et
al. (1995). Lane 1, Mock-infected U373 cells. Lane 2, Strain U1102-
infected cells.
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mid into U373 cells. By using anti-U3 serum, the U3
protein was detected in the cytoplasm, preferentially in
the perinuclear region, which was similar to that seen in
infected cells. In transfected cells, the U3 protein ap-
peared as granular patterns and accumulated in the
perinuclear region. When transfected cells were stained
dually with anti-U3 serum and PDI and examined under
the confocal imaging microscope, the staining patterns
overlapped significantly with those of an ER marker PDI
(Fig. 7). It can be concluded that this protein is present in
portions of the ER.
Identification of overexpressed U3 protein by Western
blot analysis
We next attempted to identify the U3 protein in a high
expression system by Western blot analysis, although we
could not detect this protein in infected cells by Western
blotting. To identify the protein encoded by the U3 ORF,
U3 protein derived from cell extracts from 293 cells
transfected with expression plasmid pCA3 and the Esch-
erichia coli expressing the U3 protein derived from the
bacterial expression plasmid pET-U3 were subjected to
Western analysis (Fig. 8). Plasmid pET-U3 was used to
examine whether the U3 protein was modified in the cell
because this plasmid expressed the full length of the U3
ORF protein without modification. When the transfected
cell extracts were analyzed with anti-U3 serum, a
polypeptide with an apparent molecular mass of 47,000
was detected (Fig. 8, lane 1), which was larger than the
predicted molecular mass of 43,700. A very faint band of
43 kDa was also seen (Fig. 8, lane 1). When E. coli-
expressed U3 protein was analyzed, the molecular mass
was ;43,000 (Fig. 8, lane 3). Thus, U3 protein expressed
FIG. 5. Schematic presentation of the U3 locus and U3 transcript.
(Box) The putative ORF encoded by the transcript. The ATG initiation
codon as described by Kozak (K-ATG) represents the potential start
site. (Numbers) The nt position reported by Gompels et al. (1995).
(Large arrows) Primers that were used to analyze the 59 and 39 ends of
each transcript. Each A1 at the 39 end of RNA indicates poly(A)1 site.
(Right) Sizes of cDNA molecules and the corresponding mRNAs.
FIG. 6. Cellular localization of U3 protein. Cells were infected with strain U-1102 and observed under the microscope (A-1, A-2). (A-1) Multinuclear
cells were detected in infected cells. (A-2) The IFA staining pattern of U3 antigens in U373 cells infected with virus at 72 h p.i. U3 antigen localizes
in the cytoplasm, predominantly to the perinuclear region (A-2).
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in the transfected cells appeared to undergo some mod-
ification.
Transactivation of HIV-1 LTR by HHV-6 U3 gene
Several US 22 family members of HCMV and HHV-6
have shown to transcriptional regulator functions (Col-
berg-Poley et al., 1992; Geng et al., 1992; Stasiak et al.,
1992; Kashanchi et al., 1994; Nicholas and Martin, 1994).
Thus, next we examined whether the U3 gene was able
to regulate gene expression. For this, U3 gene was fused
to an HCMV-promoter (pCA3), and its effect was exam-
ined on the expression of an HIV-LTR reporter plasmid
fused to a luciferase gene (pHL) (Fig. 9). The U3 se-
quence was able to affect the induction of HIV LTR-
luciferase expression (4.9-fold at 0.8 mg of pCA3),
whereas that of the antisense plasmid showed no sig-
nificant increase on HIV-LTR-derived luciferase activity.
The results demonstrated that the HHV-6 U3 gene was
able to transactivate the HIV LTR.
DISCUSSION
It has been reported that viruses belonging to b-herpes-
virus subfamily such as HCMV, murine CMV, HHV-6, and
HHV-7 have the consensus motifs characteristic of the
HCMV US 22 (Weston and Barrell, 1986; Chee et al., 1990;
Messerle et al., 1991; Efstathiou et al., 1992; Thomson and
Honess, 1992; Gompels et al., 1995; Nicholas et al., 1996;
Rawlinson et al., 1996). Presently, no biological function has
been determined for any member of the HCMV US22 family,
and the gene product of one member, HCMV US22, has
been identified in infected cells and shown to be an early
protein that locates in the cytoplasm and nucleus and is
secreted from the cells (Mocarski et al., 1988). It is of
interest whether genes related to the US22 family in b-her-
pesviruses would have common characteristic functions.
FIG. 7. Confocal, digital images of transfected U373 cells reacted with antibodies to U3 and PDI. U3 antigen localizes to cytoplasmic compartments
including endoplasmic reticulum. (A and D) U3 antigen stained with anti-U3 serum. (B and E) Endoplasmic reticulum stained with anti-PDI antibody.
(C) An overlaying images of in A and B. (F) An overlaid of images in D and E.
FIG. 8. Western blot analysis of expressed recombinant U3 protein.
Cell extracts from 293 cells transfected with plasmid pCA3 (lane 1) or
with control plasmid pCE (lane 2) and cell extract from E. coli ex-
pressed with plasmid pET-U3 (lane 3) were subjected to Western blot
analysis. (Arrows) The 47- and 43-kDa proteins.
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The US22 gene family have been shown to have four amino
acid sequence motifs (Efstathiou et al., 1992, Nicholas and
Martin, 1994), and each member contains at least one of
the four motifs. The region containing a motif I GXXOX-
OXWP, where O is any hydrophobic residue and X is any
residue, and a motif II OOCCXXXLXXOG of US22 family is
conserved in all family members (Efstathiou et al., 1992). In
this study, we analyzed the U3 gene of HHV-6A strain
U1102, which lies at the left end of the HHV-6 genome. The
U3 gene encodes all the four motifs of the US22 family
(Thomson and Honess, 1992; Nicholas and Martin, 1994).
We have been studying the HHV-6 U3 gene locus, and
in the present study, we first investigated the pattern of
transcripts encoded by U3 locus. The transcripts with six
different sizes were detected in poly(A)1 RNA from in-
fected U373 cells by Northern blotting (Fig. 1). After the
results of Northern blotting, mRNAs of 2.0 and 3.5 kb
were mapped within U3 gene region and were not
spliced. The other four transcripts across the U3 region
may be related to the proximate genes. These two mR-
NAs appeared to encode the same polypeptide. At
present, it is unknown which RNA is major for the protein
synthesis, but 3.5-kb transcript appeared to mainly syn-
thesize the protein; 3.5-kb transcript was mainly detected
by Northern blot analysis, and the majority of cDNA
clones had a large molecular weight (Fig. 2). By the
primer extension assay, the 59 termini of 2.0- and 3.5-kb
transcripts appeared to be the same position, which was
9 nt upstream of the first methionine codon (Fig. 3). A
TATA box-like sequence TATTTC and TATATTA existed at
positions 10–15 and 63–69 bp upstream of the cap site,
respectively, and the latter TATA box was predicted for
U3 ORF (Efstathiou et al., 1992). Because synthesis of the
RNA could be normally directed by the TATA box at
positions 30–45 bp upstream of the cap site, both TATA
box-like sequences may not fit, and the typical TATA box
may not be necessary in this region. Although the 3.5-kb
transcript could potentially encode both U3 and U2 ORF
at present, it is unknown whether it is a bicistronic mRNA
that can encode both ORFs. These results indicate that
the 2.0- and 3.5-kb transcripts are the likely transcript for
the U3 gene. For the 2.0- and 3.5-kb transcripts, the 39
end was mapped to position 9797 and 8590–8592 of
HHV-6A, respectively (Gompels et al., 1995) (Fig. 4). A
typical poly(A)1 signal sequence (AATAAA) was found
;21 nt upstream of the mapped site for the 2.0-kb tran-
script, and that (CATAAA) was located ;27 nt upstream
of the mapped site for the 3.5-kb transcript, although this
poly(A)1 signal is rare.
In infected cells, the expressed protein level seemed
to be very low; this would be due to low levels of the
transcripts. We were unable to detect the transcripts
when total RNA was used for Northern blot analysis.
Only when poly(A)1 RNA was used, transcripts were
detectable. Furthermore, we found only 15 cDNA clones
after screening 5 3 105 colonies of the cDNA library,
suggesting that the transcripts are very few. Considering
the result of the low expression of the U3 gene, this gene
product may play some role in viral gene regulation.
Furthermore, the multiple transcriptional patterns in
these gene loci are possibly important for viral gene
regulation or expression as described elsewhere in
HHV-6 (Zhou et al., 1997).
In this study, U373 cells were chosen because HHV-6A
replicates in these cells, which are adherent and in which
the expression of U3 gene product was clearly de-
tected. It has been reported that HHV-6 replicates well
in lymphocytic cells, but in the case of the round type
of cells, it is difficult to locate viral antigens in the
cytoplasm because the cytoplasmic region in lympho-
cytic cells is normally smaller than that in adherent
cells. Consequently, it is more difficult to detect viral
antigens in cytoplasm in lymphocytic cells than in
adherent cells. However, because the mRNA from the
U3 gene was detected in SupT1 cells infected with
strain U1102 and its transcriptional pattern of U3 gene
was similar between the adhesion type of U373 and
the rounded type of Sup T1 cells (data not shown), the
U3 gene might be translated more efficiently in U373
cells than in lymphocytic cells.
In general, herpesvirus genes can be classified as
immediate-early, early, and late genes. The expression of
early genes is independent of viral DNA replication, and
some of early genes are involved in gene regulation and
FIG. 9. U3 transactivates HIV LTR. CV1 cells were cotransfected with
pHL and increasing doses of U3 expression plasmid pCA3 or antisense
U3 plasmid pCA3 (AS). The amount of activator plasmid was kept
constant by addition of the control backbone plasmid pCE. After 46 h,
extracts were prepared and analyzed for luciferase activity. Each result
represent the average of three independent experiments, with error
bars representing the standard errors of the mean values.
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DNA replication. The late genes are dependent on viral
DNA replication and mainly encode structural proteins
(Honess and Roizman, 1974). The U3 protein started to be
detected by IFA at 24 h p.i. and thereafter accumulated.
Furthermore, the addition of PFA to cells infected with
HHV-6 blocked the synthesis of U3 protein. HHV-6A gene
expression in U373 cells is different from that in lympho-
cytic cells because the late antigens such as gB are
hardly detected in U373 cells infected with U1102 (data
not shown). Therefore, in U373 cells, the expression of
HHV-6 genes might be limited early-late phases. Alter-
natively, the expression levels of late genes might be
very low. Therefore, the U3 protein may be an early-to-
late antigen or late antigen. Although antigens belonging
to some of the US 22 family are expressed during the
immediate-early or early phase of infection such as
HCMV and HHV-6, U3 may express its protein during a
later phase. It was also reported that an antigen with the
US22 motifs in HHV-6 was expressed antigen during a
late phase (18–24 h p.i.) (Kashanchi et al., 1997).
Confocal IFA patterns in cells transfected and stained
with antibodies to U3 and PDI revealed that U3 protein
was present in a cytoplasmic compartment. Given its
distribution in the endoplasmic reticulum, U3 protein
might contribute to transportation of cellular and viral
proteins and inhibit or assist the function of the proteins.
It is noteworthy that a larger amount of U3 antigens
was detected in transfected cells than in infected cells,
possibly because the natural promoter of the U3 gene
was weaker than the promoter fused to the U3 coding
sequences. Also, it should be pointed out that although
we tried, we were unable to obtain a cell line constitu-
tively expressing the U3 protein, suggesting that the U3
protein may have some toxic effect on host cells in cases
of high expression. It is possible that the expression of
U3 protein may have to be maintained at a low level in
naturally infected cells.
In U3 ORF, there are two candidate methionine sites
for the initiation of translation; the translational product of
U3 is likely initiated at the first methionine after the
mRNA start site because its surrounding sequences
comply with the consensus for initiation codons de-
scribed by Kozak (1987). Furthermore, the estimated mo-
lecular masses of U3 ORF from the first and second
methionine sites are 43,150 and 41,000, respectively. Al-
though the molecular masses of the U3 proteins in trans-
fected cells were 47,000 (major) and 43,000 kDa (minor),
that of pET-U3 in E. coli was ;43,000 (Fig. 8), and a
;43,000 polypeptide was detected in vitro translation
assay (data not shown), indicating that the translation
may start from the first methionine site and that this
protein might be post-translationally modified in the
mammalian cells. In fact, this protein has two potential
N-linked glycosylation sites and an identifiable trans-
membrane anchor. Because the U3 protein localizes to
ER, migrates much slowly on an SDS gel compared with
the expected one, and has the potential N-linked glyco-
sylation sites, the U3 protein might be glycosylated.
Members of US22 family have been shown to have
transactivating functions. Our transfection studies showed
that HHV-6 U3 protein also activates transcription di-
rected by the HIV-1 LTR on the transient expression of
U3. However, this protein was localized mainly in the
cytoplasm, not in the nucleus. Because a protein with
such a transactivating property is usually detected in the
nucleus, the U3 protein may indirectly activate the pro-
moter through activating cellular factors such as NF-kB,
involving a signal transduction pathway. It has been
proposed that both HHV-6 and HIV-1 naturally infect the
same CD41 T lymphocytes in vitro, and thus HHV-6 is
considered an important cofactor for AIDS progression
(Lusso et al., 1989). Further studies on the HHV-6 genes
in HIV expression may provide a deeper understanding
of the pathogenesis of HIV.
MATERIALS AND METHODS
Cells and viruses
Umbilical cord blood mononuclear cells (CBMCs)
were isolated by centrifugation on Ficoll–Conray gradi-
ents. The cells were stimulated with 5 mg of phytohem-
agglutinin/ml for 2 or 3 days in RPMI 1640 medium
containing 10% fetal calf serum (FCS). To prepare virus
stocks, HHV-6A U1102 strain (Downing et al., 1987) was
propagated in stimulated CBMCs as shown previously
(Takeda et al., 1996). When .80% of the cells showed the
cytopathic effect (CPE), the culture of infected cells was
frozen-thawed twice; after centrifugation at 3000 rpm for
10 min, the supernatant was stored at 280° as a cell-free
virus stock. The human T cell line SupT1 and human
astrocytoma cell line U373 were used for experiments
after infection with the stock viruses.
Isolation of RNA
SupT1 and U373 cells infected with strain U1102 for
24 h were used for isolation of RNA. Total RNA was
isolated from virus- or mock-infected cells using the
method of guanidium thiocyanate–phenol–chloroform.
The RNA was fractionated by Oligotex-dT30 (Takara
Shuzo) according to the manufacturer’s protocol.
Radioactive labeling of DNA probes
Polymerase chain reaction (PCR)-amplified products
were used for hybridization as probes as shown in Fig-
ure 1b. The DNA probe was labeled with [a-32P]dCTP
using a multiprime DNA labeling system kit (Amersham).
Northern blot hybridization
For Northern blot hybridization, 10 mg of poly(A)1
RNA was subjected to electrophoresis on 1% agarose-
formaldehyde gels, blotted onto a Hybond-N nylon
135HHV-6 U3 GENE
membrane (Amersham), and hybridized to DNA probes
at 60°C in a 25 mM sodium phosphate buffer with 53
SSC, 53 Denhardt’s solution, and 15% formamide. Af-
ter hybridization, the membranes were washed at 65°
in solutions of decreasing ionic strength (23 SSC–
0.1% SDS and 13 SSC–0.1% SDS) for 30 min each,
followed by exposure to Kodak XAR films with an
intensifying screens. The 0.24–9.5-kb RNA ladder
marker was used in this study (GIBCO BRL).
Primer extension analysis
The synthetic oligonucleotide oligo 1 (59-CTCTC-
CCGAGACTGCAGCTC-39), as indicated in Figure 3, was
59 end-labeled with IRD41 (Aloka). Poly(A)1 RNA (12 mg)
was mixed in 20 ml of 13 first-strand buffer (GIBCO BRL)
and 1 mM dNTP and heated for 15 min at 70°. After
heating, annealing and the extension reaction were car-
ried out at 42° for 60 min in the presence of 200 U of
Superscript II reverse transcriptase (GIBCO BRL) with
labeled primer. The product was denatured and analyzed
on a 6% polyacrylamide–8 M urea sequencing gel on an
Li-Cor automated DNA sequencer (Aloka). Transcript ini-
tiation sites were identified by comparison with a con-
current DNA sequence using the same oligonucleotide
primer as used for generating the extension product. The
cDNA clone was used as a template for the sequencing
reactions.
39 RACE
cDNA was synthesized with a primer T7-TF 59-GTAAT-
GCGACTCACTATAGGGCTTTTTTTTTTTTTTTTT-39 using
SuperScript Preamplication System for First Strand
cDNA Synthesis (GIBCO BRL) and subjected to use for
PCR with T7 Primer (Toyobo) 59-GTAATACGACTCACTAT-
AGGGC (adapter primer) and UA3025 (59-AACTTGGAG-
GCAAGCCGACGCTGATG-39) or UA4407 (59-CGTTCAC-
GCGCCTGTGATAGATCTG-39) (Fig. 5), which was an-
nealed with the adapter and cDNA. The PCR products
were subjected to direct sequencing with the primers
UA3025 and UA4407 (Fig. 5).
Construction of cDNA library
Poly(A)1 RNA from U373 cells infected with U1102 for
24 h was used as the starting material to construct a
cDNA library. We used 5 mg of poly(A)1 RNA as the
template. cDNA synthesis was primed using both 1 mg of
oligo(dT)12–18 and 100 ng of random hexamers and
carried out with Superscript II reverse transcriptase from
Superscript Choice System for cDNA Synthesis (GIBCO
BRL), followed by insertion of the cDNA into a plasmid
vector pEF-BOS/neoA (Sagawa et al., 1996). The cDNA
library was introduced into DH5a by electroporation and
amplified, and cDNA clones were screened with 32P-
labeled PCR products as a probe of U3F (Fig. 1b).
Expression of U3 in E. coli and production of anti-U3
antisera
It was reported that ORF of U3 gene contained 1161 bp
(Gompels et al., 1995). A DNA fragment from positions
805–1161 encoding the carboxyl-terminal amino acid re-
gion of the ORF of U3 gene was isolated by PCR and
cloned in-frame into the pMALTM-c2 bacterial expres-
sion vector in the BamHI and SalI sites. The MBP-U3
fusion protein was expressed in E. coli BL21 by induction
with 0.1 mM isopropyl-b-D-thiogalacto-pyranoside (IPTG),
and the fusion protein was affinity purified (Kellerman
and Ferenci, 1982) and used for immunization of rabbits.
Subsequent booster immunizations were given with 0.3
mg of the fusion protein in Freund’s incomplete adjuvant
at 2-week intervals. Two weeks after the sixth injection,
sera were collected. The antibody was purified with
Immunopure IgG (Protein A) Purification Kit (Pierce) and
with the MBP-U3 fusion protein coupled to CNBr-acti-
vated Sepharose 4B (Pharmacia).
Antibodies
The polyclonal rabbit antiserum against the U3-carboxyl-
terminal region was used as dilutions of 1:100 for immuno-
fluorescence antibody test (IFA) and 1:500 for immunoblot-
ting. Preimmune serum and anti-MBP rabbit serum (New
England Biolabs) were also used for IFA at dilutions of 1:100
and 1:500, respectively, and for immunoblotting at dilutions
of 1:500 and 1:1000, respectively. The monoclonal antibody
to human prolyl-4-hydroxylase (hPH), the endoplasmic re-
ticulum coat protein, was obtained from Fuji Yakuhin Kogyo.
Because hPH has been shown to be identical to protein
disulfide isomerase, this antibody is referred for this report.
FITC-conjugated goat anti-rabbit immunoglobulin antibod-
ies and RITC-conjugated rabbit anti-mouse immunoglobu-
lin antibodies were obtained from DAKO. These commer-
cially obtained antibodies were used as recommended by
the manufacturers.
Construction of plasmids
The HCMV immediate-early (1E) 1-gene promoter vec-
tor, pCE, was constructed by cloning the HCMV promoter
and SV40 polyadenylation sequences from pCEP4 plas-
mid (InVitrogen) into the SalI site of pUC19 plasmid. The
HHV-6 U3 expression vector pCA3 was constructed by
inserting the PCR-amplified U3 sequence between the
NheI and XhoI sites of pCE. The sequences of the prim-
ers were 59-gctagcTGTTACTGCGAGCCCGTAA-39 for the
sense and 59-ctcgagTCATCGAACCACGTCGTGT-39 for
the antisense, where the lowercase letters indicate ad-
ditional restriction endonuclease sites. To generate an-
tisense U3 plasmid pCA3 (AS), pCE and pCA3 were
digested by NheI and XhoI and then pCE vector and U3
DNA fragment from pCA3 were filled with Klenow and
ligated in antisense orientation. A luciferase reporter
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plasmid containing HIV-1 LTR, pHL, was generated by
digestion of the CD-12 HIV-1 LTR construct with XbaI and
HindIII and subcloning into the luciferase plasmid
pGL2-B (Promega) between NheI and HindIII sites.
Cell culture and transient transfection assay
Human embryonic kidney 293 cells and U373 cells
were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FCS. 293 and U373 cells were
seeded onto 30-mm dishes containing sterile glass cov-
erslips 16 h before transfection with SuperFect (Qiagen)
according to the manufacturer’s instructions. The U3
gene-containing plasmid pCA3 and control plasmid pCE
described above (2 mg) were each transfected alone. At
48 h after transfection, the cells were collected for IFA
and Western blotting.
Indirect IFA in U1102-infected and U3
gene-transfected U373 cells
To examine the expression patterns of U3 protein, IFA
was performed by using anti-U3 rabbit serum according
to the method published previously (Takeda et al., 1996).
U373 cells were grown and maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% FCS.
After washing three times with PBS, cells were sus-
pended in 1 ml of virus solution and incubated for 60 min
at 37°C to adsorb virus, followed by centrifugation at
3000 rpm. Then, cells were washed with PBS and
seeded onto eight-chamber glasses. At 12, 24, 48, and
72 h p.i., cells were fixed in 4% formaldehyde for 15 min,
permeabilized for 2 min in PBS with 0.5% Triton X-100 at
room temperature (RT), rehydrated with sterile water, and
equilibrated with PBS. Primary antibodies were added to
monolayers on glasses, which were incubated for 30 min
at RT in a humid chamber. After glasses were washed
with PBS, secondary antibodies to FITC-conjugated goat
anti-rabbit immunoglobulin antibodies (1:200) were
added, and incubation was continued for an additional
30 min at RT. The glasses then were washed with PBS,
followed by mounting onto glass slides. The cells were
observed under a fluorescence microscope. The U3
gene-transfected cells were fixed according the method
described above and doubly stained simultaneously for
U3 and PDI with a mixture of anti-U3 rabbit serum and
mouse anti-PDI monoclonal antibody. RITC-conjugated
rabbit anti-mouse and FITC-conjugated goat anti-rabbit
immunoglobulin antibodies were used as secondary an-
tibodies. Cells were viewed with confocal imaging mi-
croscopy (Zeiss LSM).
Plasmid construction for production of U3
recombinant protein and expression of U3
protein in E. coli
The vector used in these experiments was pET-3c
(Novagen). The U3 ORF from U1102 cDNA was cloned
into NdeI and BamHI sites of pET-3c, creating pET-U3.
In this construct, translation was initiated at an initia-
tion codon located upstream of the ORF in the vector.
To synthesize the full-length U3 protein, the initiation
codon was converted to an NdeI restriction site by
PCR. The 59 primer was 59-catatgGAAACGACAAA-
GAACCGGCGTGTG-39, and contains an additional 6
bp corresponding to the NdeI restriction site. The 39
primer, 59-ggatccTCATCGAACCACGTCGTGTACGGCA-
CT-39, is complementary to the beginning of the U3
ORF and contains an additional 6 bp that encodes a
BamHI restriction site. The resulting vector, pET-U3,
encodes the full-length U3 gene product. Constructs
were introduced into E. coli BL21(DE3) pLys S. T7
polymerase expression was induced with 1 mM IPTG.
Cells were collected by centrifugation, and extracts
were prepared.
Western blot analysis
293 cells were transfected with pCA3 and pCE and
were harvested 48 h after transfection. Then, cells
were lysed in protein lysis buffer [10% glycerol, 50 mM
Tris, pH 7.4, 1% 2-mercaptoethanol] and centrifuged.
Proteins were separated by SDS–10% PAGE, trans-
ferred to nylon membranes (Amersham), and reacted
with appropriate primary antibodies. A horseradish
peroxidase-linked secondary conjugate was used, and
reactive bands were visualized using the enhanced
chemiluminescence (ECL) Detection Reagents (Amer-
sham).
Transactivation assay
The 2.5 3 105 CV1 cells/6-cm plate were transfected
by SuperFect (Qiagen). Then, 0.20 mg of the reporter
plasmid, 0.2–1.6 mg of an activator or backbone plasmid,
1 mg of pEGFP-N1 (Clontech) for observing transfection
efficacy, and 2.2 mg of pUC19 were transfected. The total
amount of transfected DNA was kept constant by adding
appropriate amounts of the control plasmid, pCE to vary-
ing amounts of the activator plasmid. Cells were har-
vested at 46 h after transfection, and the level of lucif-
erase activity was determined. The luciferase activity
was normalized for protein concentration by using the
method of Bradford (1976) with bovine serum albumin as
a standard.
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